Aspire Biopharma Achieves Key Milestone with Sublingual Aspirin Trial for Heart Attack Treatment

Aspire Biopharma Holdings, Inc., has announced promising results from its clinical trial of a new sublingual aspirin product. This formulation has shown a rapid effect on serum thromboxane B2 (TxB2), inhibiting it within just two minutes. TxB2 serves as a biomarker indicating the reduction of platelet aggregation, crucial in preventing blood clot formation during acute myocardial infarction (AMI).

The trial demonstrated that Aspire's sublingual aspirin delivered aspirin more effectively than traditional chewed tablets. This advancement could lead to faster interventions in suspected heart attacks, potentially lowering mortality rates. With over 800,000 AMI cases yearly in the U.S., Aspire aims for accelerated FDA approval by Q3 2025, highlighting the life-saving possibilities of this technology.